This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $43.30, moving +0.91% from the previous trading session.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $43.02 in the latest trading session, marking a -0.07% move from the prior day.
AstraZeneca, Merck's Lynparza Cut Risk of Breast Cancer Death
by Zacks Equity Research
Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The Zacks Analyst Blog Highlights Pfizer,Coca-Cola, Adobe, SAP SE, and Glaxo Smith Kline
by Zacks Equity Research
Pfizer,Coca-Cola, Adobe, SAP SE, and Glaxo Smith Kline are part of today's Analyst Blog.
Top Research Reports for Pfizer, Coca-Cola & Adobe
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Coca-Cola Company (KO) and Adobe Inc. (ADBE).
Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain
by Zacks Equity Research
Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.
AstraZeneca, Merck's Lynparza Gets FDA Nod for Expanded Use
by Zacks Equity Research
FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.
GlaxoSmithKline (GSK) Stock Moves -0.66%: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $40.56, marking a -0.66% move from the previous day.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $40.83, moving -1.23% from the previous trading session.
AstraZeneca (AZN), Sanofi's (SNY) RSV Vaccine Lowers Infections
by Zacks Equity Research
AstraZeneca (AZN) and Sanofi's (SNY) nirsevimab reduces lower respiratory tract infections like bronchiolitis or pneumonia caused by RSV 74.5% in infants.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $41.45, moving -1.38% from the previous trading session.
SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets
by Zacks Equity Research
Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.
Pfizer (PFE) Gets Breakthrough Therapy Status for RSV Vaccine
by Zacks Equity Research
Pfizer (PFE) is developing an RSV vaccine candidate, RSVpreF, to immunize pregnant women or older adults. The FDA grants a breakthrough therapy tag for the candidate's use in pregnant women.
VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment
by Zacks Equity Research
VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.
Allscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up
by Debanjana Dey
Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.
Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals
by Kinjel Shah
Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.
Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.
Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.
Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.
Avanos Medical (AVNS) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Avanos Medical's (AVNS) fourth-quarter 2021 results gain from strength in the chronic care segment.
Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.
Top Analyst Reports for Amazon, Home Depot & PetroChina
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Home Depot, Inc. (HD), and PetroChina Company Limited (PTR).
Tandem Diabetes (TNDM) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.
AstraZeneca (AZN) Enhertu Effective in HER2-Low Breast Cancer
by Zacks Equity Research
AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-low metastatic breast cancer.